STOCK TITAN

Adia Med (ADIA) SEC Filings

ADIA OTC
Rhea-AI Summary

Adia Med, Inc. (ADIA) reported third-quarter 2026 revenue of $454,385, versus $332,048 a year earlier, and nine-month revenue of $1,019,245 versus $521,958. It recorded a quarterly net loss of $53,015, compared with $70,376 net income, and a nine-month net loss of $271,922 versus $169,839. Nine-month operating cash use was $239,653.

ADIA disclosed substantial doubt about its ability to continue as a going concern, citing losses and dependence on higher revenue and outside capital. On September 30, 2026, ADIA and subsidiary Adia Labs agreed to sell 30% of Adia Labs to Live Oak Health LLC, doing business as QCM Biologics, for $1.5 million: $1 million cash and a $500,000 note. The buyer may purchase up to 10 more units at $50,000 each through September 30, 2028; if fully exercised and no other units are issued or transferred, ADIA would own 60%, with each side holding 50% of voting power.

The revised June 2026 statements reduce revenue and net income by $96,800 for the three- and six-month periods. Working capital was $128,369 at September 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Rhea-AI Summary

Adia Med, Inc. sold seven membership units in Adia Labs LLC to its Chief Executive Officer, Larry A. Powalisz, for an aggregate purchase price of $350,000, payable entirely in cash. The units represent a 7% membership interest and carry 7% of Adia Labs’ total voting power, assuming 100 issued units and no other units are issued or transferred at closing; economic ownership follows the units.

The agreement requires the Company’s operating agreement to be amended at closing to reflect the units and voting power. The purchase price may be used for Company or Seller corporate purposes only as jointly approved in writing by independent directors Monica Sher, M.D., and Richard Edwards, D.O. Powalisz has no unilateral authority to approve, direct, or decide how the purchase price is used.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.21%
Tags
current report
-
Rhea-AI Summary

Adia Med, Inc. (ADIA) repaid and discharged its unsecured revolving line of credit on October 9, 2026, paying lender Larry Powalisz, the company’s chief executive officer and a related party, a total of $934,970.94. Payments were $500,000 on October 7 and $434,970.94 on October 9; the latter included $74,658.94 in accrued interest, with the balance applied to principal. The lender acknowledged that all outstanding principal and accrued interest were paid in full as of October 9, 2026.

The facility was entered into on June 30, 2024, with Powalisz as lender and the company and its relevant subsidiaries, as applicable, as borrowers. Its commitment had increased over time to $1,000,000, and it bore interest at 6% per annum, calculated daily. The company stated that the facility was satisfied in full for amounts owing through October 9, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
current report
Rhea-AI Summary

ADIA, identified in the report as Adia Med, Inc. (formerly Adia Nutrition, Inc.), completed the sale of 30 of Adia Labs LLC’s 100 outstanding membership units, representing 30%, to Live Oak Health LLC, doing business as QCM Biologics, for $1.5 million. Consideration is $1 million in cash and a $500,000 promissory note. The note bears 7% annual interest on unpaid principal, with interest-only monthly payments of $2,916.67 for 48 months; the $500,000 principal plus accrued interest is due 48 months after closing.

After closing, ADIA owns 70% of Adia Labs’ units and the buyer owns 30%, but each has 50% of the voting power. ADIA granted the buyer an option to purchase up to 10 additional units for $50,000 each, exercisable in whole units through September 30, 2028. After expenses, taxes and required tax distributions, 10% of the remaining amount is reserved and the other 90% is distributed according to unit ownership within 30 days after quarter-end. ADIA may use the $1 million cash proceeds for Adia Labs or corporate purposes determined by its board.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.53%
Tags
current report
-
Form 8-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.53%
Tags
current report
-
Rhea-AI Summary

Adia Nutrition, Inc. (ADIA) has engaged Lucosky Brookman LLP as legal counsel to support a planned uplisting from the OTC Markets to the Nasdaq Capital Market or a similar senior exchange and to advise on a contemplated bridge financing transaction. Under an engagement letter dated August 14, 2026, the firm will handle preparation and filing of a Form S-1 registration statement, related SEC comment responses and amendments, the listing application, and structuring and documentation of the bridge financing, as well as related corporate matters.

Fees for these uplist and bridge financing services are fixed at $150,000, with additional amounts payable if hourly billings exceed 115% of that fee. The fee is scheduled as $30,000 at closing of the bridge financing, $50,000 upon filing the Form S-1, and the balance (plus any excess hourly amounts) at the uplisting closing. After listing on Nasdaq or the New York Stock Exchange, ongoing Exchange Act and related securities work will be billed at $8,000 per month, with other work at stated hourly rates. The firm receives expense reimbursement, customary indemnification, and a security interest in the company’s assets to secure outstanding obligations, and the agreement may be terminated by either party with written notice, subject to payment of amounts due.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
current report
Rhea-AI Summary

Adia Nutrition, Inc. reports a corporate name change to Adia Med, Inc. The company filed a Certificate of Amendment in Nevada on June 2, 2026, changing its legal name and updating its Amended and Restated Articles of Incorporation, with no other changes to articles or bylaws.

Regulatory approval of the name change from FINRA was received on July 10, 2026. Common stock continues to trade on the OTC Markets Venture Market under the ticker “ADIA”, and existing stock certificates remain valid and do not need to be exchanged. Future reports will use the new corporate name Adia Med, Inc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
-
Rhea-AI Summary

Adia Nutrition, Inc. focuses on AHSCT medical procedures for multiple sclerosis and biologic products through its Adia Med and Adia Labs segments. For the six months ended June 30, 2026, revenue rose to $661,660, mainly from medical procedures of $434,670 and biologics of $221,525, generating gross profit of $350,157.

The company still recorded a six‑month net loss of $122,107, though it achieved quarterly net income of $40,418 in the three months ended June 30, 2026. The balance sheet shows cash of $128,115, a related‑party line of credit balance of $835,312, an accumulated deficit of $16,095,589, and a stockholders’ deficit of $379,781. Management discloses “substantial doubt” about continuing as a going concern and expects to rely on increasing revenues and a $1,000,000 related‑party credit facility to fund operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
quarterly report
-
Rhea-AI Summary

Adia Nutrition, Inc. reports sharply higher activity but continued losses for the three months ended March 31, 2026. Revenue rose to $176,275, mainly from medical procedures of MS patients and sales of biologics, producing gross profit of $67,577.

The company recorded a net loss of $162,525 and an accumulated deficit of $16,136,007, and its 10-Q states there is “substantial doubt” about its ability to continue as a going concern. Cash was $136,716 with total assets of $776,868 and total liabilities of $1,197,067, including a related-party line of credit of $723,656. As of March 31, 2026, 94,404,696 Class A common shares were outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
quarterly report
Rhea-AI Summary

ADIA Nutrition, Inc. filed its annual report, detailing a transition from a former shell into an operating regenerative-medicine and biologics business focused on stem-cell therapies and supplements. In 2025, the company generated $700,508 in revenue, mainly from sales of biologics and medical procedures, but recorded a net loss of $395,464 and an accumulated deficit of $15,973,482. Management’s auditors raised substantial doubt about ADIA’s ability to continue as a going concern. ADIA operates FDA-registered perinatal tissue products under Section 361, runs a Winter Park, Florida clinic, and uses a related-party credit line and small equity raises to fund operations while it scales its stem-cell and supplement activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
annual report

FAQ

How many Adia Med (ADIA) SEC filings are available on StockTitan?

StockTitan tracks 11 SEC filings for Adia Med (ADIA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Adia Med (ADIA)?

The most recent SEC filing for Adia Med (ADIA) was filed on November 16, 2026.